Related Experiment Video
Updated: Jul 10, 2026

The Examination of Peroxidase-Positive Leukocytes in Semen
Published on: January 19, 2024
A 24-year-old man taking PrEP with unusual syphilis test results
Marika L Forsythe1, Hong-Kee Lee1,2
1Department of Pathology, University of Chicago Pritzker School of Medicine, Chicago, IL, US.
Introduction:
The antiretroviral regime emtricitabine-tenofovir disoproxil fumarate (Truvada [Gilead Sciences]) is a type of pre-exposure prophylaxis (PrEP) therapy used for the prevention and management of HIV infections. This protection, however, cannot be applied to other sexually transmitted infections (STIs), with many studies observing an increase in STI rates among individuals using PrEP.
Methods:
A 24-year-old man who had recently started PrEP with emtricitabine-tenofovir disoproxil fumarate was found to have a clinically significant elevation in syphilis total antibody count on STI screening, but his rapid plasma reagin (RPR) and Treponema pallidum particle agglutination (TP-PA) results remained negative. The patient was subsequently treated for a syphilis infection.
Results:
Post-treatment testing showed a negative syphilis total antibody result. The patient was suspected to have undergone treponemal antibody seroreversion, a rare but previously documented phenomenon following successful treatment.
Discussion:
This case highlights the possible effect of PrEP on the immune system, requiring closer surveillance to prevent acquisition of other STIs.
Related Concept Videos
Sexually Transmitted Infections
Serum Laboratory Studies, Stool Test, Breath Test
Disorders of the Male Reproductive System
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Genital Herpes

